Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Borawski, J.
Right arrow Articles by Mysliwiec, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borawski, J.
Right arrow Articles by Mysliwiec, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1996) 11: 2444-2448
© 1996 European Renal Association-European Dialysis and Transplant Association


research-article

Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy

J. Borawski, A. Rydzewski, M. Mazerska, M. Kalinowski, K. Pawalak and M. Mysliwiec

Department of Nephrology and Internal Medicine, Bialystok Medical School Poland

Correspondence and offprint requests to: Corresponding and offprint requests to: Jacek Borawski MD, Department of Nephrology and Internal Medicine, Bialystok Medical School, ul. Zurawia 14, PL-15–540 Bialystok, Poland

BACKGROUND.: Amelioration of the anaemia of chronic renal failure and subsequent improved haemorheology result in correction of bleeding diathesis as evidenced by shortening of the skin bleeding time (BT). However, the relationship between the haematocrit and platelet-vessel wall interactions in haemodialysis (HD) patients under recombinant human erythropoietin (rHuEpo) therapy, assessed by platelet aggregation in response to ristocetin is more complex and somewhat inconsistent.

METHODS.: We investigated the relationship between haemoglobin (Hb) levels and whole blood ristocetininduced platelet aggregation (electric impedance method) in 28 HD patients treated with rHuEpo, and with normal BT. The measurements were repeated in 16 subjects after having reduced platelet aggregability with orally administered ketanserin.

RESULTS.: Ristocetin-induced platelet aggregation in the whole group was comparable to those found in 21 age-matched healthy subjects (normals) and in 25 HD patients not treated with rHuEpo (uraemics). Interestingly, a significant inverse correlation between this aggregation and Hb concentration was found (r = –0.392, P<0.05). In the group of 16 patients, the preketanserin aggregation was more intensive than in the normals and uraemics (P<0.05). Ketanserin produced a fall in ristocetin-induced platelet aggregation (P<0.02), prolongation of the BT (P<0.02) and, unexpectedly, a decrease in serum Epo concentration (P<0.0002) and the Hb level (P<0.001). Again, an inverse correlation between depressed ristocetin-induced platelet aggregation and lowered Hb concentration was found (r= –0.590, P<0.02). Moreover, a strong positive correlation between the extent of preketanserin platelet aggregation and the decrease in the intensity of this process that followed the trial was observed (r=0.919, P<0.000005). There were no changes in other haematological parameters or arterial blood pressure.

CONCLUSIONS.: Considering the role of von Willebrand factor and fibrinogen in mediating ristocetin-induced platelet aggregation, and enhanced synthesis and/or release of these macromolecules in response to uraemia or inflammation, we suggest that exaggerated whole-blood platelet aggregability to ristocetin points to blunted erythropoiesis in HD patients on rHuEpo therapy.

Keywords: erythropoietin; ketanserin; platelet aggregation; ristocetin; uraemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
J. Borawski, B. Naumnik, K. Pawlak, and M. Mysliwiec
Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response
Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1442 - 1447.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.